Amphastar Pharmaceuticals, Inc. AMPH

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Over the past six months, Amphastar Pharmaceuticals has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $24.97, representing a healthy 29.8% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals earnings season.

Recent Price Moves Put Amphastar Pharmaceuticals in Focus Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent share price swings, with the stock closing at $23.18 and showing mixed performance over the past week, month, past 3 months, and year. Short term, Amphastar Pharmaceuticals has seen momentum build, with a 30-day share price return of 11.55% and a 90-day share price return of 19.55%. Yet the 1-year total shareholder return is down 21.21%, pointing to a recovery that...

Amphastar Pharmaceuticals stock presents a tricky mix for investors, with a steep 3 year share price decline set against valuation checks that now lean cheap on traditional multiples. Over the past 3 years the share price has fallen about 53.6%, which leaves current holders facing a deep drawdown and raises the question of whether the stock has been pushed too far down. Future expectations for Amphastar Pharmaceuticals around the durability of its product portfolio and its ability to convert...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portfolio and new product introductions. Management pointed to robust demand for commercial brands like BAQSIMI and Primatene MIST, as well as the successful launch of ipratropium bromide, as key drivers behind the quarter’s growth. CEO Bill Peters emphasized the company's progress in expanding manufacturing capabilities and advancing its develop

AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on year to $183.9 million. Its non-GAAP profit of $0.91 per share was 48.3% above analysts’ consensus estimates.

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.